Jail-Based hep c cure program shows promise in pilot study
NCT ID NCT06953479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a low-barrier hepatitis C treatment program can help people in jail start and finish their medication more easily. Forty adults awaiting trial at the Rhode Island Department of Corrections will receive a 12-week course of the antiviral drug Epclusa. If released early, they take the remaining pills with them and get support from community health workers. The goal is to cure their hepatitis C and see if this approach could be used in other jails.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C (HCV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rhode Island Department of Corrections
RECRUITINGCranston, Rhode Island, 02920, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can hormone therapy change liver health? a new study investigates
- Can a video help new parents make informed choices about biobanking?
- A nudge toward better heart health: can online food pantries steer shoppers to healthier choices?
- New tool could help doctors identify patients needing end-of-life care earlier
- Virtual program aims to keep joint replacement patients moving while they wait
- Self-Sampling could boost cervical cancer screening for women with HIV